CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients.
Baris Boralİbrahim TuncerFiliz KibarSalih CetinerSuade Ozlem BadakEmrah SalmanEmrah KocEren ErkenAkgun YamanPublished in: Turkish journal of medical sciences (2023)
The results showed that the improvement in treatment response to the therapy in RA patients could be because of the enhancement in the CD39/adenosine (ADO) pathway. Therefore, therapies targeting the CD39/ADO pathway in T cells may improve RA treatments.
Keyphrases
- rheumatoid arthritis patients
- disease activity
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- poor prognosis
- nk cells
- peritoneal dialysis
- prognostic factors
- ankylosing spondylitis
- stem cells
- high dose
- interstitial lung disease
- mesenchymal stem cells
- patient reported